Trial Profile
The study evaluating Minimal Residual Disease and the Switch from Imatinib to Dasatinib at the end of induction (day +70) in Ph+ ALL patients: The Ph+RALL Protocol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 20 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology